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Background
Breast cancer is the most prevalent cancer in the world due
to high incidence and favorable prognoses. Relapse is the
major cause of mortality and will occur in up to 65% of
patients with node-positive disease. Thus, effective long-
term protection strategies are needed for preventing
relapse. One approach that has generated interest in
recent years is cancer vaccines. One of the problems with
the translation of cancer vaccines is that multiple boosters
are required in order to generate high-avidity memory
immunity that is able to recognize naturally processed
antigens. Our goal in this study was to determine if the
need for boosters could be eliminated by preconditioning
the immune system with anti-CD25 antibodies, which is
known to deplete regulatory T cells, the latter of which are
known to regulate the development of high-avidity mem-
ory T cells.
Materials and methods
We first developed a single peptide vaccine to generate
neu-specific CTL immunity in the Neu-T mice. Neu-T
mice have targeted expression of the activated rat neu in
breast tissue that occurs at 3–4 weeks of age, and these
mice develop spontaneous breast tumors at 15–17 weeks.
Results
The vaccine peptide, TYVPANASL (p66–74), was pre-
dicted by the SYFPEITHI algorithm http://www.syf
peithi.com to bind to mouse MHC class I, H-2d and was
admixed with IFA and CpG. In the non-tolerant, Balb/c
mice, vaccination prevented tumor development with
only a single immunization. In the tolerant neu-T mice,
the same vaccine succeeded in preventing spontaneous
and transplanted tumors but only when given with
repeated boosters. The response was durable as it was
found that 80% of mice remained tumor free by week 45
of age. In order to determine if CD25+ Tregs may be pre-
venting or regulating the development of high avidity
memory immunity, anti-CD25 monoclonal antibodies
were used to deplete Tregs prior to immunization. Follow-
ing depletion, a single vaccination administered at week
10 following birth, when diffuse atypical hyperplasia is
already evident in the mammary glands, vaccination
induced a sufficient CTL response that has kept 100% of
Neu-T mice tumor free until week 31. Immune monitor-
ing revealed that Treg depletion resulted in higher avidity
T cells following a single immunization.
Conclusion
Our results show that by combining a strong adjuvant
(CpG) and an immunogenic peptide, we can induce an
immune response capable of preventing spontaneous
tumors when repetitive vaccinations are administered.
Importantly, the need for boosters is reduced when Tregs
are depleted prior to immunization. Removing or reduc-
ing the need for booster immunizations may facilitate the
clinical translation of cancer vaccines for prevention of
breast cancer development and relapse.
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